Patents Examined by Joanne Hama
-
Patent number: 11365265Abstract: The present invention relates to combinations of anti-C5 antibodies and antigen-binding fragments which have been determined to exhibit superior activity relative to that of a single anti-C5 antibody or fragment. The combinations include anti-C5 antibodies and antigen-binding fragments which do not compete with one another from C5 binding. Bispecific antibodies comprising antigen-binding domains which do not compete and/or bind the same epitope on C5 are also provided. Compositions and therapeutic methods relating to such anti-C5 combinations and bispecific antibodies are provided herein.Type: GrantFiled: December 12, 2018Date of Patent: June 21, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventor: Kishor Devalaraja-Narashimha
-
Patent number: 11345746Abstract: The present invention provides a fully human antibody specifically inhibiting Connexin 26, characterized in that it is a recombinant immunoglobulin having the structure of scFv-Fc, wherein scFv refers to a single-chain antibody comprising a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is SEQ ID NO: 1, the amino acid sequence of the light chain variable region is SEQ ID NO: 2, and Fc refers to constant region. The present invention uses the first 41-56 amino acid sequence of extracellular region of Connexin26 as an antigen, the sequence thereof is KEVWGDEQADFVCNTL. Through the biochemical analysis and immunofluorescence identification of the antibody obtained by single-chain antibody phage display library and screening technology, it was confirmed that the antibody provided by the present invention could specifically recognize Connexin 26 and inhibit its hemichannel activity.Type: GrantFiled: December 14, 2016Date of Patent: May 31, 2022Assignee: SHANGHAITECH UNIVERSITYInventors: Zhihu Qu, Guang Yang, Fabio Mammano, Francesco Zonta
-
Patent number: 11345748Abstract: Provided herein are compounds, compositions, and methods of identifying compounds that neutralize the ability of the cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from agonizing CB1 signaling in peripheral tissues. Further provided herein are methods of treating a disorder associated with dysregulated or abnormal hepatic de novo lipogenesis and/or hepatic selective insulin resistance by inhibiting cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from binding and agonizing CB1.Type: GrantFiled: December 9, 2019Date of Patent: May 31, 2022Assignee: President and Fellows of Harvard CollegeInventors: Gökhan S. Hotamisligil, Kosei Eguchi
-
Patent number: 11332534Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.Type: GrantFiled: July 31, 2019Date of Patent: May 17, 2022Assignee: Cephalon, Inc.Inventors: Doris Shim Siew Chen, Lynn Dorothy Poulton, Adam Clarke, David Jose Simon Laine, Matthew Pollard, Bridget Ann Cooksey, Anthony Doyle, Jason William Gill
-
Patent number: 11332524Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.Type: GrantFiled: March 22, 2019Date of Patent: May 17, 2022Assignees: Surface Oncology, Inc., Adimab LLCInventors: Jonathan Hill, Scott Chappel, Michael Gladstone, Bianka Prinz, Andrew Lake, Christine Miller, Kerry White, Jing Hua, Pamela M. Holland, Matthew Rausch, Devapregasan Moodley
-
Patent number: 11318158Abstract: A method is provided of decreasing or increasing the activity of a Pappalysin polypeptide by decreasing or increasing the level of interacting Pappalysin and stanniocalcin polypeptides. A method is also provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of a stanniocalcin polypeptide. Moreover, a method is provided of preventing, treating or ameliorating a clinical condition in a mammalian subject, such as a human being, said method comprising administering to said mammalian subject, such as human being an effective amount of an agent capable of antagonizing interaction of a stanniocalcin polypeptide with a Pappalysin polypeptide.Type: GrantFiled: October 11, 2019Date of Patent: May 3, 2022Assignee: Aarhus UniversitetInventors: Claus Oxvig, Jakob Hauge Mikkelsen, Malene Runge Jepsen
-
Patent number: 11299548Abstract: A gene combination capable of high-efficiency expression of rhNGF is provided to optimize gene expression regulation components of a recombinant human nerve growth factor. The gene combination enhances expression of rhNGF. As shown by experiments, the gene combination is capable of high-efficiency expression of a recombinant human nerve growth factor (rhNGF) with natural activity in a eukaryotic expression system.Type: GrantFiled: November 8, 2018Date of Patent: April 12, 2022Assignee: XINTRUM PHARMACEUTICALS, LTD.Inventors: Hai Chen, Hongliang Sun, Yi Zhang, Yuesheng Wang
-
Patent number: 11292847Abstract: The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody.Type: GrantFiled: May 10, 2019Date of Patent: April 5, 2022Assignee: REGENERON PHARMACEUTICALS, INC.Inventor: Ashish Bansal
-
Patent number: 11286302Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.Type: GrantFiled: July 24, 2018Date of Patent: March 29, 2022Assignee: Genentech, Inc.Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
-
Patent number: 11267862Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.Type: GrantFiled: September 11, 2020Date of Patent: March 8, 2022Assignee: AKSTON BIOSCIENCES CORPORATIONInventors: Thomas M. Lancaster, Todd C. Zion
-
Patent number: 11261229Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.Type: GrantFiled: September 11, 2020Date of Patent: March 1, 2022Assignee: AKSTON BIOSCIENCES CORPORATIONInventors: Thomas M. Lancaster, Todd C. Zion
-
Patent number: 11254720Abstract: The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.Type: GrantFiled: January 11, 2019Date of Patent: February 22, 2022Assignees: On Target Therapeutics LLC, Trustees of Tufts College, Tufts Medical CenterInventors: Charles Cohen, Krishna Kumar, Jamie Raudensky Doyle, Alan S. Kopin
-
Patent number: 11235040Abstract: In one embodiment a vaccine composition comprises two or three AChR subunit constructs and an adjuvant. In some embodiments the AChR subunit construct is an AChR ?1 subunit construct, an AChR ?1 subunit construct, an AChR ? subunit construct, an AChR ? subunit construct, or an AChR ? subunit construct. In another embodiment, the invention provides a method of treating myasthenia gravis in a patient in need thereof, comprising administering a vaccine composition comprising one or more acetylcholine receptor subunit constructs selected from the group consisting of AChR ?1 subunit, AChR ?1 subunit, AChR ? subunit, AChR ? subunit, AChR ? subunit, a fragment thereof, and a combination thereof, and an adjuvant.Type: GrantFiled: September 14, 2015Date of Patent: February 1, 2022Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Jon Lindstrom, Jie Luo
-
Patent number: 11160873Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.Type: GrantFiled: July 5, 2018Date of Patent: November 2, 2021Assignees: Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd., Olivia Newton-John Cancer Research InstituteInventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
-
Patent number: 11142795Abstract: Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.Type: GrantFiled: March 15, 2018Date of Patent: October 12, 2021Assignee: ACADEMIA SINICAInventors: Shie-Liang Hsieh, Ya-Lang Huang, Tsung-Yu Tsai
-
Patent number: 11136398Abstract: The present invention provides binding polypeptides (e.g., antibodies or fragments thereof) that specifically bind to a target antigen (e.g., a human antigen, e.g., human PDGFR?) with high affinity. The invention also provides, libraries of binding polypeptides, pharmaceutical compositions, as well as nucleic acids encoding binding polypeptides, recombinant expression vectors and host cells for making such binding polypeptides. Methods of using binding polypeptide of the invention to diagnose and treat disease are also encompassed by the invention.Type: GrantFiled: February 17, 2020Date of Patent: October 5, 2021Assignee: X-BODY, INC.Inventors: Yan Chen, Richard W. Wagner, Csaba Pazmany
-
Patent number: 11129926Abstract: The present disclosure provides for a medical device or a substrate coated with polydopamine which is further linked to ligands such as antibodies and/or antibody fragments. The polydopamine coating and the ligands may be linked through a linker such as an organic polymer.Type: GrantFiled: April 13, 2018Date of Patent: September 28, 2021Assignee: OrbusNeich Medical PTE. LTD.Inventor: Michael J. B. Kutryk
-
Patent number: 11124554Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.Type: GrantFiled: May 6, 2020Date of Patent: September 21, 2021Assignee: Howard Hughes Medical InstituteInventors: Scott Sternson, Peter Lee, Christopher Magnus
-
Patent number: 11091542Abstract: The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: GrantFiled: December 14, 2016Date of Patent: August 17, 2021Assignee: UCB BIOPHARMA SRLInventors: Ralph Adams, Pallavi Bhatta, Emma Dave, Sam Philip Heywood, David Paul Humphreys, Diane Marshall, Daniel John Lightwood
-
Patent number: 11084853Abstract: This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.Type: GrantFiled: July 7, 2017Date of Patent: August 10, 2021Assignee: Howard Hughes Medical InstituteInventors: Scott Sternson, Peter Lee, Christopher Magnus